Bolag
Qlife Holding är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av IVD-enheter. Enheterna används som biomarkörstester i blod och används som komplement till övriga tester inom vården. Samarbete utförs även med övriga aktörer på marknaden. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret beläget i Helsingborg.
Qlife Holding AB ("Qlife" or the "Company") is pleased to provide a business update for the first half of 2026. During the period, the Company has continued to advance multiple strategic partnership initiatives across both the pharmaceutical and diagnostics sectors, while maintaining steady progress on its Egoo Health platform and regulatory milestones.
Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, announces that it has entered into a feasibility agreement with a global pharmaceutical company with the objective to evaluate a specific biomarker on Egoo Health related to a therapeutic application. The feasibility agreement is fully funded by the pharma company.
Qlife Holding AB höll den 27 maj 2026 årsstämma varvid i huvudsak följande beslut fattades.
Approaching strategic partnerships
Qlife Holding AB:s (“Qlife”) årsredovisning finns från och med idag tillgänglig på Qlifes hemsida: https://qlifeholding.com/sv/investerare/finansiella-rapporter.
Aktieägarna i Qlife Holding AB, org.nr 559224-8040, kallas till årsstämma den 27 maj 2026 kl. 11.00 i Moll Wendén Advokatbyrås lokaler på Stortorget 8 i Malmö.
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE
Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, today provides a business update covering recent milestones, ongoing progress, and priorities for the coming quarters.
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE
Qlife Holding AB (“Qlife” or the “Company”) today announces that, following the recently communicated strong interest from hospitals in China in evaluating the Egoo platform, its strategic partner Hipro Biotechnology will accelerate the path towards commercialisation based on its full responsibility for the continued development, local adaptation, regulatory approval of Egoo in China.